替比夫定对慢性乙型肝炎患者血清中IL-6和IL-18的影响  

Efficacy of Telbivudine for patients of chronic hepatitis B in the IL-6 and IL-18

作　　者：彭晓明[1] 王煜[2] 刘娅[2] 

机构地区：[1]宁夏医科大学,银川750004 [2]宁夏医科大学附属医院感染疾病科

出　　处：《中国实用医药》2011年第13期17-18,共2页China Practical Medicine

摘　　要：目的观察替比夫定(LdT)治疗前后慢性乙型肝炎(CHB)患者血清中白细胞介素6(IL-6)和白细胞介素18(IL-18)水平的变化,探讨替比夫定对CHB患者细胞免疫功能的影响。方法设立健康对照组100例,CHB组96例,用ELISA方法检测各组中IL-6和IL-18的变化;CHB组加用替比夫定抗病毒治疗24周,观察治疗前后血清中IL-6、IL-18及病毒学指标的变化。结果①CHB患者血清中IL-6和IL-18水平较健康对照组明显升高,差异有统计学意义(P值均<0.01);②替比夫定抗病毒治疗后较治疗前血清中IL-6、IL-18及HBVDNA水平均下降,差异有统计学意义(P<0.05)。结论替比夫定通过抑制HBV复制,能够降低CHB患者血清中IL-6和IL-18的水平,可以改善CHB患者的细胞免疫功能。Objective To observethe of serum interleukin 6（IL-6） and interleukin 18（IL-18） levels before and after telbivudine（LdT） treatment on patients with chronic hepatitis B,and to explore the efficacy of Telbivudine on cellular immune function in patients with CHB.Methods Establish healthy control group of 100 cases,CHB group of 96 patients.Measuring the serum IL-6 and IL-18 levels and changes in each groups by ELISA.CHB patients in the treatment group were treated with Telbivudine for 24 weeks,observed changes of the serum IL-6 and IL-18 and virological indicators before and after the treatment.Results ① The level of serum IL-6 and IL-18 in CHB group were significantly higher than the healthy control group,the comparison between either groups were significant differences（P0.01）.② The serum IL-6,IL-18 and HBV DNA levels were decreased after the treatment with telbivudine,the comparison between either groups were significant differences（P0.05）.Conclusion Telbivudine can reduce the serum IL-6 and IL-18 levels and improve immune function in patients with CHB by inhibiting HBV replication.

关 键 词：替比夫定 肝炎 乙型 白细胞介素6 白细胞介素18 

分 类 号：R512.62[医药卫生—内科学]